Astellas Collaborates with CytomX Therapeutics to Develop Probody T-Cell Engaging Bispecific Therapies for Cancer Indications

 Astellas Collaborates with CytomX Therapeutics to Develop Probody T-Cell Engaging Bispecific Therapies for Cancer Indications

Astellas Collaborates with CytomX Therapeutics to Develop Probody T-Cell Engaging Bispecific Therapies for Cancer Indications

Shots:

  • CytomX to receive $80M up front, ~$1.6B as pre/ clinical & commercial milestones, along with royalties on sales and will be responsible for research and discovery activities, up to clinical candidate selection
  • The companies partnered for several initial programs and will utilize CytomX’s Probody therapeutic technology for CD3 bispecific targets and its expertise in targeting multiple Ab modalities to the tumor micro-environment
  • For a specified number of targets, prior to the initiation of the first clinical study, CytomX to get an option to fund a pre-determined portion of development cost and may receive a pre-specified portion of profits in the US and royalties on sales (ex-US) and may later exercise its option for co-commercialization rights in the US

Click here ­to­ read full press release/ article | Ref: PRNewswire  | Image: Astellas

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post